Risk Factors for Febrile Neutropenia during Chemotherapy for HIV-Related Lymphoma
Journal of Korean Medical Science
;
: 1468-1471, 2012.
Article
in English
| WPRIM
| ID: wpr-178283
ABSTRACT
We evaluated risk factors for neutropenic fever and febrile prolonged neutropenia during vincristine-including chemotherapy to treat HIV-related lymphoma to investigate whether protease inhibitor (PI) treatment is associated with infectious complications due to drug interactions with chemotherapeutic agents. We included all HIV patients who received chemotherapy including vincristine for lymphoma at a single referral center in 1999-2010. Neutropenic fever was defined as absolute neutrophil count < 500 cells/microL with body temperature over 38degrees C; and prolonged neutropenia was defined if it persisted over 7 days. CODOX-M/IVAC and Stanford regimens were considered high-risk regimens for prolonged neutropenia. We analyzed 48 cycles of chemotherapy in 17 HIV patients with lymphoma. There were 22 neutropenic fever and 12 febrile prolonged neutropenia events. In multivariate analysis, neutropenic fever was associated with old age and low CD4 cell count, but not with PI use or ritonavir-boosted PI use. Low CD4 cell count and high-risk regimens were associated with febrile prolonged neutropenia. Neutropenic fever and febrile prolonged neutropenia is associated with old age, low CD4 cell count, and high-risk regimens, but not PI use, in HIV patients undergoing chemotherapy including vincristine for lymphoma.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Vincristine
/
Body Temperature
/
HIV Infections
/
Multivariate Analysis
/
Retrospective Studies
/
Risk Factors
/
Age Factors
/
Lymphoma, AIDS-Related
/
CD4 Lymphocyte Count
/
Fever
Type of study:
Etiology study
/
Observational study
/
Risk factors
Limits:
Adult
/
Humans
/
Male
Language:
English
Journal:
Journal of Korean Medical Science
Year:
2012
Type:
Article
Similar
MEDLINE
...
LILACS
LIS